On Monday afternoon, just a week after getting Sarepta to pull its Duchenne gene therapy from the market and suggesting it would likely never return, the FDA made a shocking reversal and will let the company start treating some patients again.
Today on Post-Hoc Live, I spoke with Baird biotech analyst Brian Skorney about what happened, whether we're seeing the consequence of a politically sensitive (or vulnerable) FDA, and what it means for the future of one of biotech's most controversial companies.
Skorney has followed Sarepta for years, and has been a candid voice about what the last two volatile weeks have meant for the company. You won't want to miss this episode.
— Drew
↧